Sarepta’s gene therapy Elevidys misses primary goal in phase 3 DMD trial 31-Oct-2023 By Liza Laws Sarepta Therapeutics has hit a setback as its approved gene therapy Elevidys missed the primary goal of a phase 3 trial in children aged 4 through 7 years with the inherited disease Duchenne muscular dystrophy (DMD).
